US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inspire Corporate Bond ETF

23.92

-0.0200-0.08%

Volume:50.14K

Turnover:1.20M

Market Cap:385.11M

PE:- -

High:23.99

Open:23.98

Low:23.89

Close:23.94

Loading ...

Overview Company News Filings

BRIEF-Inspire 500 ETF (Ptl) Surpasses $300 Million In Assets Under Management

Inspire 500 ETF (Ptl) Surpasses $300 Million in Assets Under Management

THOMSON REUTERS

TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

Microba Says Test Studies Detect 60% More Pathogens Missed by Routine Methods in Bowel Disease Patients

MT Newswires Live

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

Grammy Award Winning Artist Knows How Math Can Help Prevent Cancer

ACCESS Newswire

Spyre Therapeutics Announces Grants of Inducement Awards

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

AbbVie Stock Rises 16% Year to Date: Time to Buy, Sell or Hold?

Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody

Organovo Provides Business Update

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Press Release: Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

ACCESS Newswire

Press Release: Organovo Announces Reverse Stock Split

Kaspa’s Crescendo Hardfork Approaching Fast: Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/IBD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","market":"US","secType":"STK","nameCN":"Inspire Corporate Bond ETF","latestPrice":23.92,"timestamp":1751054400000,"preClose":23.94,"halted":0,"volume":50140,"delay":0,"floatShares":16100000,"shares":16100000,"eps":0,"marketStatus":"Pre-Mkt","change":-0.02,"latestTime":"06-30 06:21:56 EDT","open":23.9823,"high":23.99,"low":23.8851,"amount":1200092.146835,"amplitude":0.004382,"askPrice":29.14,"askSize":100,"bidPrice":19.07,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1751290200000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":23.92,"sharesOutstanding":16100000,"nav":23.88,"aum":384494668.95,"dividendRate":0.042224,"bidAskSpread":0.001911,"postHourTrading":{"tag":"盘后","latestPrice":23.92,"preClose":23.92,"latestTime":"16:04 EDT","volume":3,"amount":71.76,"timestamp":1751054643139},"volumeRatio":0.981528316364688},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","floatShares":16100000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.981528316364688,"shares":16100000,"dividePrice":1.01,"high":23.99,"amplitude":0.004382,"preClose":23.94,"low":23.8851,"week52Low":22.84,"pbRate":"--","week52High":25.49,"institutionHeld":0,"latestPrice":23.92,"eps":0,"divideRate":0.042224,"volume":50140,"delay":0,"ttmEps":0,"open":23.9823,"prevYearClose":23.44,"prevWeekClose":23.92,"prevMonthClose":23.74,"prevQuarterClose":23.75,"fiveDayClose":23.96,"twentyDayClose":23.73,"sixtyDayClose":23.77},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2539257011","title":"BRIEF-Inspire 500 ETF (Ptl) Surpasses $300 Million In Assets Under Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2539257011","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539257011?lang=en_us&edition=fundamental","pubTime":"2025-05-29 20:02","pubTimestamp":1748520136,"startTime":"0","endTime":"0","summary":"BRIEF-Inspire 500 ETF (Ptl) Surpasses $300 Million In Assets Under ManagementMay 29 (Reuters) - INSPIRE 500 ETF (PTL) SURPASSES $300 MILLION IN ASSETS UNDER MANAGEMENTSource text: ID:nPn6zqBv6a ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nTUA8NX2HZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RISN","GLRY","ISMD","WWJD","PTL","FDLS","IBD","BIBL","BLES"],"gpt_icon":0},{"id":"2539212256","title":"Inspire 500 ETF (Ptl) Surpasses $300 Million in Assets Under Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2539212256","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539212256?lang=en_us&edition=fundamental","pubTime":"2025-05-29 18:00","pubTimestamp":1748512807,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nTUA8NX2HZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RISN","ISMD","FDLS","WWJD","IBD","BLES","PTL","GLRY","BIBL"],"gpt_icon":0},{"id":"2533056586","title":"TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years","url":"https://stock-news.laohu8.com/highlight/detail?id=2533056586","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533056586?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:05","pubTimestamp":1746446700,"startTime":"0","endTime":"0","summary":"Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92. SAN DIEGO, Calif., May 5, 2025 /PRNewswire/ -- Johnson & Johnson  today announced new data from the TREMFYA  Phase 3 QUASAR long-term extension  study in adults with moderately-to-severely active ulcerative colitis . These data are among 24 abstracts highlighting the Company's research being presented at Digestive Disease Week  2025.Data from the QUASAR LTE studydemonstrate patients treated with TREMFYA sustained clinical and endoscopic efficacy at Week 92: a, 1. 72% of patients were in clinical remissionb with 99% of those patients remaining corticosteroid free for 8 or more weeks through Week 92.Patients treated with TREMFYA sustained clinical and endoscopic remission regardless of prior biologic and/or JAK inhibitor treatment history.\"With these findings, TREMFYA shows the powerful impact it can have in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/tremfya-guselkumab-delivers-sustained-clinical-120500832.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tremfya-guselkumab-delivers-sustained-clinical-120500832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2468319806.SGD","IE0002270589.USD","BK4568","SG9999002232.USD","IE0009355771.USD","LU2505996509.AUD","BK4559","LU0792757196.USD","IE00B1BXHZ80.USD","LU0345770308.USD","BK4504","LU0345770993.USD","IE00B7SZLL34.SGD","LU0640476718.USD","LU1674673691.USD","LU1929549753.HKD","LU2089984988.USD","BK4581","LU1718418525.SGD","LU1066051811.HKD","JNJ","LU1244550494.USD","LU1935042991.SGD","CD","LU0889566641.SGD","LU1244550221.USD","LU1894683264.USD","LU1196500208.SGD","IE00B42XCP33.USD","LU0466842654.USD","LU1674673428.USD","IBD","BK4588","LU1778281490.HKD","LU2347655156.SGD","IE00BFTCPJ56.SGD","LU1267930813.SGD","LU1732800096.USD","LU1894683348.USD","LU0345769631.USD","LU2505996681.GBP","LU1914381329.SGD","BK4116","IE00B2B36J28.USD","IE00BSNM7G36.USD","LU1032955483.USD","IE00BLSP4239.USD","LU0320765646.SGD","IE00B19Z3B42.SGD","LU1280957306.USD"],"gpt_icon":0},{"id":"2533586580","title":"Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001","url":"https://stock-news.laohu8.com/highlight/detail?id=2533586580","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533586580?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:00","pubTimestamp":1746446400,"startTime":"0","endTime":"0","summary":"SPY001 is a novel, half-life extended α4β7 antibody in development for the treatment of Inflammatory Bowel Disease . SPY001 pharmacokinetic  data up to eight months continues to support a potential best-in-class profile, including a half-life more than three times that of vedolizumab. SPY001 pharmacodynamic  data up to eight months showed that a single dose of SPY001 resulted in rapid and sustained saturation of α4β7 receptors at expected Phase 2 trough concentrations. Spyre presented results out to eight months of follow up from its SPY001 Phase 1 program.Updated results from our ongoing Phase 1 trial of SPY001, our novel half-life extended α4β7 antibody for the treatment of IBD, continues to show that SPY001 is well tolerated, has a half-life of more than three-fold compared to vedolizumab based on population PK modeling, and sustains target engagement at expected Phase 2 trough concentrations. This longer follow-up data strengthens the potential for SPY001 to demonstrate improved in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-poster-presentations-120000455.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-poster-presentations-120000455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PK","SYRE","BK4181","BK4139","BK4007","LENZ","LU1169589451.USD","PD","LU1169590202.USD","BK4023","IBD","BK4218"],"gpt_icon":0},{"id":"2532839942","title":"Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2532839942","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532839942?lang=en_us&edition=fundamental","pubTime":"2025-05-02 04:20","pubTimestamp":1746130800,"startTime":"0","endTime":"0","summary":"– Company advances SL-325 program with an IND filing expected in the third quarter of 2025 –。– Cash balance of approximately $60.9 million as of March 31, 2025, expected to fund operations into 2027 –。“All IND-enabling activities and regulatory interactions remain on-track to initiate the Phase 1 clinical trial for SL-325 in the third quarter of this year. We believe SL-325 is fundamentally differentiated in its approach to targeting the clinically validated DR3/TL1A pathway and could potentially provide best-in-class clinical remission rates for IBD patients,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck. “Spending last quarter continued to come in line with expectations, and wind-down activities associated with the discontinued oncology programs have now been substantially completed. We continue to be well-positioned to fund operations into 2027, beyond the results from our Phase 1 clinical trial for SL-325.”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shattuck-labs-reports-first-quarter-202000143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IBD","STTK","BK4139"],"gpt_icon":0},{"id":"2531108719","title":"Microba Says Test Studies Detect 60% More Pathogens Missed by Routine Methods in Bowel Disease Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2531108719","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531108719?lang=en_us&edition=fundamental","pubTime":"2025-04-30 06:35","pubTimestamp":1745966135,"startTime":"0","endTime":"0","summary":"Microba Life Sciences  said that studies of its MetaPanel gastrointestinal pathogen test found that 40% of inflammatory bowel disease  patients tested positive for gastrointestinal pathogens, and over 60% of the pathogens would have been missed using standard diagnostic methods, according to a Tuesday statement by the company.MetaPanel was designed to identify pathogens not detected by conventional tests to help clinicians avoid unnecessary treatments, reduce treatment failures, and minimize the need for surgery, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAP.AU","IBD","BK7124"],"gpt_icon":0},{"id":"2531999377","title":"Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2531999377","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531999377?lang=en_us&edition=fundamental","pubTime":"2025-04-30 04:01","pubTimestamp":1745956860,"startTime":"0","endTime":"0","summary":"-- XENITH-UC, a Phase 2b study of XmAb942 in participants with ulcerative colitis, to begin in the second half of 2025 --. -- Single and multiple doses of XmAb942 are well tolerated and safety profile is consistent with the anti-TL1A drug class --. -- XmAb942 half-life supports a 12-week maintenance dosing interval in XENITH-UC --. Based on these positive interim results, Xencor is initiating the XENITH clinical program, advancing XmAb942 into a Phase 2b study in patients with moderate-to-severely active UC , with the expected study start in the second half of 2025.The Phase 1 study of XmAb942 in healthy volunteers is a randomized, double-blind, placebo-controlled, dose-escalation trial, exploring intravenous  and subcutaneous  dose administration, at three escalating dose levels. The interim results re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xencor-announces-positive-interim-results-200100434.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4116","CD","IBD","BK4139","XNCR"],"gpt_icon":0},{"id":"2529330452","title":"Grammy Award Winning Artist Knows How Math Can Help Prevent Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2529330452","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529330452?lang=en_us&edition=fundamental","pubTime":"2025-04-22 20:30","pubTimestamp":1745325000,"startTime":"0","endTime":"0","summary":"Anthony Hamilton experiences how Medtronic is using AI to help detect colon polyps. NORTHAMPTON, MA / ACCESS Newswire / April 22, 2025 / Grammy Award winning singer and songwriter Anthony Hamilton underwent a colonoscopy for the first time in his mid-20's, right around the same time as his first record deal.\"I was having digestive issues and when the doctors did a colonoscopy they found polyps,\" he remembers. \"Ever since then I've been really aware of how I feel, trying to live right and eat right and stay ahead of problems whenever I can. Regular colonoscopies help me do that.\". In the 30-or-so-years since his first colonoscopy, Hamilton's doctors found polyps during several checkups, and they discovered more at his most recent exam in early 2025. But that checkup was different than all the rest.\"One of the polyps we found was pretty hard to see,\" said Dr. Lanre Jimoh, a gastroenterologist at Carolina Digestive Health Associates in Charlotte, North Carolina. \"But with the help of the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/grammy-award-winning-artist-knows-123000030.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1116320737.USD","LU2271345857.HKD","IE00BFXG1179.USD","LU1116320901.HKD","BK4585","BK4082","LU0320765489.SGD","LU2111349929.HKD","LU1291159041.SGD","LU1571399168.USD","IE00B3T34201.USD","BK4533","LU0072461881.USD","BK4588","LU0496365809.HKD","LU0211326755.USD","IE00BQXX3F31.USD","LU0070302665.USD","LU0162691827.USD","LU2023251221.USD","LU1989771016.USD","BK4566","LU0208291251.USD","LU1989764748.USD","LU2028103732.USD","LU0976567544.SGD","IBD","LU0211326839.USD","LU2089283258.USD","LU0265550359.USD","LU1983299246.USD","IE000M9KFDE8.USD","LU0265550946.USD","MDT","LU0211331839.USD","LU1989764664.SGD","LU2468319806.SGD","LU0158827948.USD","LU2089284900.SGD","LU2089984988.USD","IE00BQXX3D17.EUR","IE00BQXX3C00.GBP","LU0158827781.USD"],"gpt_icon":0},{"id":"2525730381","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2525730381","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525730381?lang=en_us&edition=fundamental","pubTime":"2025-04-05 04:05","pubTimestamp":1743797100,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., April 4, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc.  , a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 93,200 shares of common stock of Spyre to five non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended . The stock options were approved on April 1, 2025 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-200500867.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-200500867.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IBD","BK4139","SYRE","LENZ"],"gpt_icon":0},{"id":"2524441554","title":"Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2524441554","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524441554?lang=en_us&edition=fundamental","pubTime":"2025-04-03 05:00","pubTimestamp":1743627600,"startTime":"0","endTime":"0","summary":"AUSTIN, TX and DURHAM, NC, April 02, 2025  -- Shattuck Labs, Inc.  , a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor  superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present at and participate in one-on-one meetings at the 24th Annual Needham Virtual Healthcare Conference, taking place April 7–10, 2025.Conference DetailsFormat: Presentation and one-on-one meetingsPresenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive OfficerDate: April 9, 2025Time: 3:00 PM EDTWebcast link: HERE. About SL-325SL-325 is a potential first-in-class Death Receptor 3  blocking antibody designed to achieve a complete and durable blockade of the clinically validated DR3/TL1A pathway. Shattuck’s preclinical studies demonstrate high affinity binding and superior activity over TL1A antibodies, and offer a data-driven rationale for targeting the TNF r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shattuck-labs-announces-participation-upcoming-210000962.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["STTK","BK4139","BK4137","IBD","HCSG"],"gpt_icon":0},{"id":"2524541514","title":"AbbVie Stock Rises 16% Year to Date: Time to Buy, Sell or Hold?","url":"https://stock-news.laohu8.com/highlight/detail?id=2524541514","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524541514?lang=en_us&edition=fundamental","pubTime":"2025-04-02 22:06","pubTimestamp":1743602760,"startTime":"0","endTime":"0","summary":"AbbVie ABBV stock has gained 16.1% so far this year compared with an increase of 4.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below. The stock is also trading above its 50-day and 200-day moving averages.AbbVie has successfully navigated the loss of exclusivity  of its blockbuster drug, Humira, by launching two other successful new immunology medicines, Skyrizi and Rinvoq, which are performing extremely well, bolstered by approvals in new indications and should support top-line growth in the next few years.AbbVie expects to return to robust revenue growth in 2025 following the Humira LOE. AbbVie has been on an acquisition spree lately in its core space of immunology. However, the company faces several near-term headwinds like Humira’s biosimilar erosion, increasing competitive pressure on cancer drug, Imbruvica, and a slow market growth trend for Juvederm fillers in the United States and China.AbbVie has several early/mid","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbvie-stock-rises-16-date-140600657.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1804176565.USD","LU0672654240.SGD","LU1712237335.SGD","LU1057294990.SGD","LU2602419157.SGD","BK4116","IE00B1BXHZ80.USD","LU0823416689.USD","LU1983299246.USD","SG9999014898.SGD","LU0198837287.USD","LU0466842654.USD","LU2089984988.USD","LU2129689605.HKD","LU0965509101.SGD","SG9999001176.USD","LU1037948897.HKD","ABBV","LLY","LU0708995401.HKD","LU2063271972.USD","IBD","LU1232071149.USD","LU1061106388.HKD","LU1929549753.HKD","LU2491049909.HKD","LU0708994859.HKD","LU1720051108.HKD","LU0097036916.USD","BK4007","LU0985320562.USD","IE00BVYPNV92.GBP","LU1267930490.SGD","LU1718418525.SGD","LU2237438978.USD","CD","SG9999018857.SGD","LU1244550221.USD","LU0158827948.USD","LU1732800096.USD","LU0320765646.SGD","LU0203201768.USD","LU2237443978.SGD","LU2347655156.SGD","LU1035775433.USD","LU1989772923.USD","LU1496350171.SGD","LU1366192091.USD","LU0256863902.USD"],"gpt_icon":1},{"id":"2524603264","title":"Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=2524603264","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524603264?lang=en_us&edition=fundamental","pubTime":"2025-04-02 20:05","pubTimestamp":1743595500,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April  02, 2025  (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment appro","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/02/3054219/37000/en/Organovo-Provides-Update-on-Cash-and-Nasdaq-Continued-Listing-Requirements.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNQmain","IE00BKPKM429.USD",".IXIC","NQmain","IE00B64PRP62.GBP","BK4139","SQQQ","IE00B3QW5Z07.USD","BK4585","TQQQ","PSQ","USAW.SI","LU2095319765.USD","LU2210150020.SGD","QID","NDAQ","TSYW.SI","LU2210149790.SGD","BK4112","BK4588","NVIW.SI","ONVO","IE00BGHQF748.EUR","USJW.SI","IBD","QLD"],"gpt_icon":1},{"id":"2522573773","title":"Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177","url":"https://stock-news.laohu8.com/highlight/detail?id=2522573773","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522573773?lang=en_us&edition=fundamental","pubTime":"2025-03-28 19:30","pubTimestamp":1743161400,"startTime":"0","endTime":"0","summary":"Clinical Remission: Achieved in 33% of PL8177-treated patients versus 0% on placebo after eight weeks of treatment.Clinical Response : Demonstrated in 78% of PL8177-treated patients versus 33% on placebo after eight weeks of treatment .Symptomatic Remission: Achieved in 56% of PL8177-treated patients versus 33% on placebo after eight weeks of treatment.Clinical remission was achieved in 33%  of PL8177-treated patients versus 0%  on placebo.Clinical response is defined per FDA Guidance  as a decrease from baseline in themMS of greater than or equal to 2 points and at least a 30% from baseline, and a decrease in rectal bleeding subscore of greater than or equal to 1","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/palatin-announces-positive-topline-results-113000236.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/palatin-announces-positive-topline-results-113000236.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IBD","PTN","BK4139","SFS"],"gpt_icon":0},{"id":"2522595385","title":"Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2522595385","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522595385?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"Preclinical data demonstrates that SPY003 is highly potent and has potential forquarterly or biannual dosing, suggesting opportunity for improved efficacy andconvenience over first-generation anti-IL-23 monoclonal antibodies. Interim pharmacokinetic and safety data from healthy volunteers for SPY003 anticipatedin the second half of 2025. SPY003 is an investigational, novel, extended half-life monoclonal antibody targeting IL-23, being developed for the potential treatment of IBD. IBD is a chronic condition characterized by inflammation in the gastrointestinal tract and encompasses two main disorders: ulcerative colitis and Crohn's disease. In the United States, it is estimated that approximately 2.4 million individuals currently have IBD. In head-to-head preclinical studies, SPY003 demonstrated equivalent potency to risankizumab in inhibiting pSTAT signaling and IL-17 production and exhibited significantly longer half-life in non-human primates with the potential to deliver dosing in h","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-first-participant-200500981.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-first-participant-200500981.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IBD","BK4218","PK","SYRE","LENZ","BK4139","BK4181"],"gpt_icon":0},{"id":"2522824370","title":"Organovo Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522824370","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522824370?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:05","pubTimestamp":1743077100,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 27, 2025  -- Organovo Holdings, Inc.  , a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease  today provided a business update.Organovo’s 3D human cellular models of both Crohn’s disease and ulcerative colitis are used by the company to evaluate therapeutic opportunities. Organovo believes that targets and therapies that it finds attractive based on predictive date from these models, made with primary cells from IBD patients, have a greater chance of success in clinical trials. Stated Organovo Executive Chairman Keith Murphy, “As we demonstrated in 2024 with FXR, we can position an asset for a significant return to investors using our 3D human cellular models of IBD. We expect to tailor our going forward business plan to leverage our newly replenished capital levels to pursue such opportunities.”","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/organovo-provides-business-120500269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1061106388.HKD","LU0079474960.USD","IE0002141913.USD","LU0094547139.USD","LU1093756325.SGD","LU0238689110.USD","LU0882574055.USD","LU0471298694.HKD","LU0354030438.USD","LU2106854487.HKD","LU0689472784.USD","LU1291159041.SGD","LU2265009873.SGD","BK4533","IE00BK4W5M84.HKD","LU2237443549.SGD","LU2491049909.HKD","LU0203202063.USD","LU1974910355.USD","BK4007","LU2237443978.SGD","LU1093756168.USD","SGXZ31699556.SGD","IE0009355771.USD","LLY","SG9999014898.SGD","LU1069344957.HKD","IBD","LU2237443895.HKD","LU0203201768.USD","LU2491050154.USD","LU2237443622.USD","IE00B4R5TH58.HKD","LU1868836914.USD","LU1917777945.USD","LU1868837300.USD","ONVO","LU2264538146.SGD","IE00B2B36J28.USD","LU2237443382.USD","LU1868837136.USD","LU2602419157.SGD","LU2237438978.USD","LU2211815571.USD","SGXZ51526630.SGD","LU0122379950.USD","LU2468319806.SGD","LU2089984988.USD","LU1064131342.USD","LU0466842654.USD"],"gpt_icon":0},{"id":"2522375405","title":"Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2522375405","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522375405?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:00","pubTimestamp":1743073200,"startTime":"0","endTime":"0","summary":"– Presented preclinical non-human primate  data at the 20th Congress of European Crohn’s and Colitis Organization in Inflammatory Bowel Diseases 2025  for SL-325, a potentially first-in-class blocking antibody to DR3, the receptor for TL1A; data demonstrated favorable safety profile, full receptor occupancy, lack of DR3 agonism –。– SL-325 advances toward Phase 1; on track for IND filing in the third quarter of 2025 –。– Cash balance of approximately $73.0 million as of December 31, 2024, expected to fund operations into 2027 –。AUSTIN, TX and DURHAM, NC, March 27, 2025  -- Shattuck Labs, Inc.  , a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor  superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided recent business highlights.Shattuck’s lead product candidate, SL-325, is a potentially","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shattuck-labs-reports-fourth-quarter-110000089.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IBD","STTK","BK4139"],"gpt_icon":0},{"id":"2522800949","title":"Press Release: Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2522800949","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522800949?lang=en_us&edition=fundamental","pubTime":"2025-03-25 23:25","pubTimestamp":1742916300,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 25, 2025  -- Organovo Holdings, Inc.  , a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease , today announced the successful close of the sale of its FXR program, including lead asset FXR314, to Eli Lilly and Company  .   The transaction was completed on March 25, 2025.With the closing, Organovo receives an upfront payment, with future milestones to be paid as FXR314 hits key regulatory and commercial milestones. Lilly is acquiring all commercial and intellectual property rights to Organovo's FXR program for worldwide development and will be responsible for all future clinical development.Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional  human tissues as candidates for drug development. The company has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, archit","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","LU2602419157.SGD","LU0471298777.SGD","SG9999017495.SGD","LU1623119135.USD","LU2063271972.USD","LU0203201768.USD","LU1064131342.USD","LU1868837300.USD","LU2237443622.USD","SG9999014880.SGD","BK4534","LU2461242641.AUD","LU0708995401.HKD","LU0109391861.USD","IE0009355771.USD","SG9999014906.USD","LU2237443465.HKD","LU0466842654.USD","LU1988902786.USD","ONVO","LU0106261372.USD","LU1057294990.SGD","LU1291159041.SGD","LLY","IE0004445239.USD","LU1868836757.USD","LU1035775433.USD","LU0417517546.SGD","LU1917777945.USD","LU0256863902.USD","LU1983299246.USD","LU0289739699.SGD","SGXZ51526630.SGD","IE00BK4W5M84.HKD","IBD","LU0471298694.HKD","LU0456855351.SGD","LU2106854487.HKD","LU0354030511.USD","LU2360106947.USD","SG9999014898.SGD","LU1720051108.HKD","BK4139","FXR","LU1548497426.USD","LU0385154629.USD","SG9999015986.USD","LU0096364046.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2521725882","title":"Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha","url":"https://stock-news.laohu8.com/highlight/detail?id=2521725882","media":"ACCESS Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521725882?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:00","pubTimestamp":1742817600,"startTime":"0","endTime":"0","summary":"BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc.  , a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its novel oral antibody, TH023. In a murine model, a proprietary protease enzyme stabilized platform demonstrated successful delivery of infliximab, a tumor necrosis factor-alpha  inhibitor, in serum with concentrations detected being significantly higher than the standard serum trough concentration needed for antibody efficacy in immunology indications via injection . These findings represent a significant step towards developing a more convenient and potentially patient-preferred alternative to currently available infliximab treatments, which are administered via intravenous infusion or subcutaneous injection.The Company announced last year through a partnership with Intract Pharma, an exclusive license to INT-023 (now","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tharimmune-announces-positive-results-novel-120000890.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","THAR","PK","IBD","BK4218","PBC","BK4139"],"gpt_icon":0},{"id":"2520183653","title":"Press Release: Organovo Announces Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2520183653","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520183653?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:05","pubTimestamp":1742385900,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 19, 2025  -- Organovo Holdings, Inc. , a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease , today announced that it will effect a 1-for-12 reverse stock split of its issued and outstanding common stock that will become effective at 5:00 p.m. Eastern Time on Thursday, March 20, 2025. Organovo's common stock will commence trading on a reverse stock split-adjusted basis at the opening of the market on Friday, March 21, 2025.Following the reverse stock split, Organovo's common stock will continue to trade on the Nasdaq Capital Market under the symbol \"ONVO\" with a new CUSIP number of 68620A302.Organovo's transfer agent, Continental Stock Transfer & Trust Company, will provide information to stockholders regarding their stock ownership following the reverse split and cash in lieu of fractional share payments, if applicable. Stockholders holding their shares in book-entry form or through a bank, broker or oth","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBD","ONVO","NQmain","BK4139"],"gpt_icon":0},{"id":"2518635063","title":"Kaspa’s Crescendo Hardfork Approaching Fast: Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2518635063","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518635063?lang=en_us&edition=fundamental","pubTime":"2025-03-12 16:44","pubTimestamp":1741769082,"startTime":"0","endTime":"0","summary":"Kaspa is making headway with its development inside the blockchain space. The Proof-of-Work L1 protocol has provided additional information concerning its expansive Crescendo Hardfork. This upgrade seeks to increase the network’s block rate from 1 to 10 blocks per second .Recently, the protocoltook to X to announce that Testnet 10  has fully transitioned to 10 BPS. This milestone is critically important for the blockchain following the Hardfork activation on March 7, 2025.TN10 aims to transform Kaspa into one of the swiftest PoW blockchains with the help of its revolutionary GHOSTDAG protocol that permits the parallel creation and confirmation of blocks. This successful shift establishes a clear agenda for the next milestone, which will be monumental for the platform and its global decentralized blockchain infrastructure.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/67d1497bf908dc328c14ed31/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["FAST","BK4567","BK4104","BK4588","IE00BFXG0V08.USD","IE00BYQQ9H92.USD","IE00B5TLWC47.USD","IBD","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":131,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBD\",params:#limit:5,,,undefined,":[{"date":"2025-06-26","symbol":"IBD","amount":0.0953,"announcedDate":"2025-06-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-26","defaultRemindTime":1750944600000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-26","currency":"USD","dateTimestamp":1750910400000,"payDate":"2025-07-01"},{"date":"2025-05-23","symbol":"IBD","amount":0.0809,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-23","defaultRemindTime":1748007000000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-28","payableDate":"2025-05-23","currency":"USD","dateTimestamp":1747972800000,"payDate":"2025-05-28"},{"date":"2025-04-25","symbol":"IBD","amount":0.0799,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-25","defaultRemindTime":1745587800000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-30","payableDate":"2025-04-25","currency":"USD","dateTimestamp":1745553600000,"payDate":"2025-04-30"},{"date":"2025-03-27","symbol":"IBD","amount":0.092,"announcedDate":"2025-03-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-27","defaultRemindTime":1743082200000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-27","currency":"USD","dateTimestamp":1743048000000,"payDate":"2025-04-01"},{"date":"2025-02-24","symbol":"IBD","amount":0.0728,"announcedDate":"2025-02-21","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-24","defaultRemindTime":1740407400000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-03","payableDate":"2025-02-24","currency":"USD","dateTimestamp":1740373200000,"payDate":"2025-03-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBD\",market:\"US\",,,undefined,":[{"executeDate":"2017-08-16","recordDate":"2017-08-18","paymentDate":"2017-08-23","value":0.0405,"currency":"USD"},{"executeDate":"2017-09-18","recordDate":"2017-09-19","paymentDate":"2017-09-25","value":0.0292,"currency":"USD"},{"executeDate":"2017-10-16","recordDate":"2017-10-17","paymentDate":"2017-10-23","value":0.0347,"currency":"USD"},{"executeDate":"2017-11-16","recordDate":"2017-11-17","paymentDate":"2017-11-28","value":0.0389,"currency":"USD"},{"executeDate":"2018-01-29","recordDate":"2018-01-30","paymentDate":"2018-02-05","value":0.0269,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBD\",market:\"US\",delay:false,,,undefined,":{}}}